FDA-Approved
FDA-approved means a compound has been cleared by the US Food and Drug Administration for a specific clinical use based on completed clinical trials demonstrating safety and efficacy. Semaglutide and Tirzepatide are FDA-approved peptide therapeutics; most research peptides are not.
Overview
The FDA approval process requires a New Drug Application (NDA) or Biologics License Application (BLA) supported by the full dataset from Phase 1, 2, and 3 clinical trials plus manufacturing quality data. FDA-approved status means the compound can be legally prescribed and dispensed as a pharmaceutical in the US for its approved indication(s). Research peptides that lack FDA approval cannot be marketed or sold for human use and exist in the 'research chemical' regulatory space. The existence of FDA-approved GLP-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound) distinguishes these compounds from the broader research peptide market in terms of regulatory status, quality assurance, and available human evidence.
Related Terms
Related Peptide Profiles
Frequently asked questions
Which peptide therapeutics are currently FDA-approved?+
Several peptide-based drugs are FDA-approved, including Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound), insulin analogues, and Bremelanotide (PT-141/Vyleesi). Most research peptides are not FDA-approved.
Can a doctor prescribe a non-FDA-approved peptide?+
In the US, physicians can prescribe certain compounded medications off-label, but the regulatory landscape around compounded peptides (particularly GLP-1 analogues) has been evolving. This area involves complex legal and regulatory nuance.
Does FDA approval mean a peptide is completely safe?+
FDA approval means benefits outweigh risks for the approved indication under studied conditions. All approved drugs have side effect profiles; post-market surveillance continues to identify rare adverse events after approval.